|
|
|
|
|
|
|
|
|
|
|
|
|
<TABLE> <S> <C>
<ARTICLE> 5
<CURRENCY> U.S. DOLLAR
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> OCT-31-2000
<PERIOD-START> NOV-01-1999
<PERIOD-END> JUL-29-2000
<EXCHANGE-RATE> 1
<CASH> 95,616
<SECURITIES> 0
<RECEIVABLES> 421
<ALLOWANCES> 40
<INVENTORY> 3,089
<CURRENT-ASSETS> 103,149
<PP&E> 44,265
<DEPRECIATION> 19,867
<TOTAL-ASSETS> 127,880
<CURRENT-LIABILITIES> 12,717
<BONDS> 0
0
0
<COMMON> 249
<OTHER-SE> 113,146
<TOTAL-LIABILITY-AND-EQUITY> 127,880
<SALES> 2,140
<TOTAL-REVENUES> 2,143
<CGS> 3,506
<TOTAL-COSTS> 3,506
<OTHER-EXPENSES> 22,631<F1>
<LOSS-PROVISION> (26)
<INTEREST-EXPENSE> 50
<INCOME-PRETAX> (29,282)
<INCOME-TAX> 0
<INCOME-CONTINUING> (29,282)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (29,282)
<EPS-BASIC> (1.24)
<EPS-DILUTED> 0
<FN>
<F1>OTHER EXPENSES ARE FOR R&D INCURRED IN DEVELOPING PRODUCT FOR MARKET.
</FN>
</TABLE>
|
|